Gene expression profiling to predict response to neoadjuvant docetaxel and capecitabine for breast cancer

被引：0
|
作者：
Korde, L.
Zujewski, J.
McShane, L.
Lukes, L.
Lebowitz, P.
Swain, S.
Finney, R.
Hunter, K.
机构：
[1] Natl Canc Inst, Bethesda, MD USA
[2] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 103卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [41] Semi-quantitative gene expression profiling for therapy prediction in a breast cancer neoadjuvant therapy study applying docetaxel/epirubicin/cyclophosphamide.
    Schlotter, CM
    Vogt, U
    Tidow, N
    Kemming, D
    Bosse, U
    Bonk, U
    Ergoenc, Y
    Adiguezel, H
    Egbert, M
    Brandt, BH
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S226 - S226
  • [42] Peripheral blood gene signatures predict response to neoadjuvant chemotherapy in breast cancer patients
    Axelrod, Margaret L.
    Gonzalez-Ericsson, Paula I.
    Sun, Xiaopeng
    Bergman, Riley E.
    Donaldson, Joshua
    Tolaney, Sara M.
    Krop, Ian E.
    Garrido-Castro, Ana C.
    Sanders, Melinda E.
    Mayer, Ingrid A.
    Balko, Justin M.
    CANCER RESEARCH, 2021, 81 (04)
  • [43] High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy
    Rau, Kun-Ming
    Su, Yu-Li
    Li, Shan-Hsuan
    Hsieh, Meng-Che
    Wu, Shis-Chung
    Chou, Fong-Fu
    Chiu, Tai-Jan
    Chen, Yen-Hao
    Liu, Chien-Ting
    MOLECULAR MEDICINE REPORTS, 2017, 16 (05) : 7185 - 7190
  • [44] Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer
    Friedman, Judah
    Dunn, Rodney L.
    Wood, David
    Vaishampayan, Ulka
    Wu, Angela
    Bradley, Deborah
    Montie, James
    Sarkar, Fazlul H.
    Shah, Rajal B.
    Hussain, Maha
    JOURNAL OF UROLOGY, 2008, 179 (03): : 911 - 915
  • [45] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
    Ayers, M
    Symmans, WF
    Stec, J
    Damokosh, AI
    Clark, E
    Hess, K
    Lecocke, M
    Metivier, J
    Booser, D
    Ibrahim, N
    Valero, V
    Royce, M
    Arun, B
    Whitman, G
    Ross, J
    Sneige, N
    Hortobagyi, GN
    Pusztai, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2284 - 2293
  • [46] Gene expression profiles can predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin and docetaxel in primary breast cancer
    不详
    BREAST, 2005, 14 : S21 - S21
  • [47] Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy
    Dressman, HK
    Hans, C
    Bild, A
    Olson, JA
    Rosen, E
    Marcom, PK
    Liotcheva, VB
    Jones, EL
    Vujaskovic, Z
    Marks, J
    Dewhirst, MW
    West, M
    Nevins, JR
    Blackwell, K
    CLINICAL CANCER RESEARCH, 2006, 12 (03) : 819 - 826
  • [48] Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer
    Drobniene, Monika
    Breimelyte, Dominyka
    Sadzeviciene, Ieva
    Sabaliauskaite, Rasa
    Valkiuniene, Ruta Barbora
    Meskauskas, Raimundas
    Dabkeviciene, Daiva
    Jarmalaite, Sonata
    BREAST, 2025, 80
  • [49] HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in operable breast cancer.
    Learn, PA
    Yeh, IT
    McNutt, M
    Chisholm, GB
    Pollock, BH
    Rousseau, DL
    Sharkey, FE
    Cruz, AB
    Kahlenberg, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 853S - 853S
  • [50] Oral Vinorelbine and Capecitabine Plus Bevacizumab in Recurrent Inflammatory Breast Cancer: Gene Profiling and Response to Treatment
    Fumagalli, L.
    Curigliano, G.
    Locatelli, M.
    Bagnardi, V.
    Bertolini, F.
    Mancuso, P.
    Giudici, S.
    Goldhirsch, A.
    CANCER RESEARCH, 2010, 70
12345